| Entity / subtype | Typical presentation | Key molecular alteration(s) | Key diagnostic tests / IHC | Typical management approaches | Key quantitative / epidemiologic / prognostic data |
|---|---|---|---|---|---|
| Cervical rhabdomyosarcoma (mostly embryonal; rare pleomorphic) | Often adolescents/young women; vaginal bleeding, vaginal tissue prolapse, abdominal pain/urinary frequency; can mimic a cervical polyp (pqac-00000003) | DICER1 association reported in cervical ERMS; pathogenic DICER1 variation noted in literature/case reports (pqac-00000014) | MRI/CT/B-ultrasound used but nonspecific; RMS-marker IHC supportive of diagnosis (pqac-00000003) | Radical surgery or fertility-sparing conservative resection plus chemotherapy; management should be age- and fertility-tailored (pqac-00000003) | “Only 0.5% of primary RMSs are located in the cervix”; 12-case series age 15–50 years, median 17; 10/11 followed patients tumor-free (90.9%); median survival 91 months; 1/4 fertility-sparing patients conceived (25%) (pqac-00000003) |
| DICER1-associated cervical sarcoma | Irregular vaginal bleeding; exophytic cervical tumor in an 18-year-old (pqac-00000014) | DICER1 mutation; proposed distinct DICER1 sarcoma entity (pqac-00000014) | Histology with high mitotic activity; IHC: CD56+, calponin+, p53 wildtype, weak panCK <5%; CD34-, S100-, SMA-, desmin-, MyoD1-, caldesmon-, ER-, PR- (pqac-00000014) | Fertility preservation discussion, oocyte cryopreservation, local resection, doxorubicin + ifosfamide; radiation avoided to preserve fertility in reported case (pqac-00000014) | Primary cervical sarcomas estimated at ~1.3% of cervical tumors; carcinosarcoma ~50%, leiomyosarcoma/adeno­sarcoma next, remaining ~9% heterogeneous group; reported tumor 8.5 × 7 × 2.5 cm, Ki-67 90%, up to 15 mitoses/HPF; patient tumor-free at last follow-up (pqac-00000014) |
| Extraosseous Ewing sarcoma of the cervix | Vaginal bleeding with cervical mass; usually small round blue cell tumor presentation (pqac-00000002) | EWSR1–FLI1 fusion in most ES; case confirmed EWSR1–FLI1; EWS/FLI occurs in ~85% and other EWS–ETS fusions in ~15% of ESFT (pqac-00000002) | H&E small round blue cells; IHC positive CD99, NKX2.2, FLI1; FISH showing EWSR1 disruption; NGS confirming fusion; MRI and FDG-PET used (pqac-00000002) | Multimodal treatment: hysterectomy-based surgery plus adjuvant/induction chemotherapy, sometimes radiotherapy following ES paradigms (pqac-00000002) | ES is mostly osseous, with “only about 20% occurring outside the bone”; reported cervical tumor 2.5 × 2.1 × 1.8 cm; disease-free at 1 year in case report (pqac-00000002) |
| NTRK-rearranged spindle cell sarcoma / neoplasm of uterine cervix | Often pre/perimenopausal women with abnormal bleeding/menorrhagia or cervical polypoid mass; fibrosarcoma-like spindle cell tumor with cervical predilection (pqac-00000013, pqac-00000012) | Recurrent NTRK fusions including TPM3::NTRK1, TFG-NTRK3, NUMA1::NTRK1; NTRK rearrangement drives constitutive Trk activation (pqac-00000013, pqac-00000012) | Pan-TRK and CD34 usually diffuse positive; S100 may be negative in some cases; FISH and RNA/targeted NGS are emphasized as confirmatory tests (pqac-00000013, pqac-00000012, pqac-00000010) | Surgery is the initial treatment of choice; TRK inhibitors are important targeted options for recurrent/metastatic disease, and selective Trk inhibitors are specifically highlighted (pqac-00000013, pqac-00000012) | Literature estimates vary: “less than 50” uterine NTRK-rearranged sarcomas described in one 2024 report; another review summarized 61 female-genital-tract cases (54 cervix, 7 corpus), mean age 39 years, mean tumor size 7.0 cm; NTRK1-fused tumors may present earlier and have more favorable outcomes (pqac-00000013, pqac-00000012) |
| COL1A1–PDGFB fusion uterine sarcoma at cervix | Vaginal bleeding with cervical/vaginal mass; reported in older women including postmenopausal patients (pqac-00000001) | COL1A1–PDGFB fusion activating PDGFB/PDGFRB signaling (pqac-00000001) | RNA sequencing/NGS or FISH required for confirmation; IHC often CD34 positive, while TRK/S100/myogenic markers/hormone receptors often negative; differential includes leiomyoma, LMS, HGESS (pqac-00000010, pqac-00000001) | Surgery is standard in localized disease; early precise diagnosis may allow benefit from imatinib (pqac-00000001, pqac-00000010) | Only five prior uterine cases plus the reported additional case; reported ages 43–82 years (average 56.7, median 53.5); one imatinib-treated patient’s intra-abdominal mass shrank from 22.4 to 6.5 cm before progression at 14 months (pqac-00000010) |
| Cervical leiomyosarcoma | Usually abnormal vaginal bleeding, often peri­menopausal; rare cervical smooth muscle sarcoma (pqac-00000004) | No single defining alteration summarized in retrieved cervix-specific evidence; generally considered part of complex uterine LMS biology (pqac-00000004) | Pathology criteria suggested include ≥5 cm, infiltrative margins, ≥5 mitoses/10 HPF, and moderate–severe atypia; smooth muscle marker expression helps in differential diagnosis (pqac-00000004, pqac-00000010) | Complete surgical excision with negative margins is primary treatment; approaches in reports range from radical hysterectomy to trachelectomy/wide local excision; role of lymphadenectomy limited/uncertain (pqac-00000004) | Described as “exceedingly rare”; lymphatic spread is low; prognosis favored by complete excision but overall optimal management remains uncertain because of rarity (pqac-00000004) |
| Cervical adenosarcoma | Rare Müllerian adenosarcoma, sometimes asymptomatic or incidentally detected; may coexist with other cervical pathology (pqac-00000007) | No specific recurrent cervical molecular alteration captured in retrieved recent evidence; uterine adenosarcoma classified as epithelial-mesenchymal tumor (pqac-00000007) | Histopathology and IHC confirm diagnosis; awareness is important because preoperative CT/curettage and frozen section may miss malignancy (pqac-00000007) | Hysterectomy ± bilateral adnexectomy in reported case; surgery remains main approach in early-stage disease (pqac-00000007) | Rarely arises in cervix; case report emphasizes that diffuse growth in uterine cavity/cervical canal without symptoms is “even rarer”; patient recovered well after surgery with follow-up (pqac-00000007) |


*Table: This table summarizes the main cervical sarcoma subtypes identified in the retrieved evidence, focusing on presentation, molecular features, diagnostics, management, and quantitative findings. It is useful as a compact reference for comparing these rare entities and their actionable biomarkers.*